Tag
A validated set of 17 quality indicators (QIs) for lupus nephritis, derived from the 2025 EULAR recommendations, shows variable adherence in practice and an association between higher adherence and lower damage accrual in a tertiary-care co
Spatially distinct macrophage subsets interact with heterogeneous myofibroblast populations in lupus nephritis, driving maladaptive fibrosis and chronic kidney injury. Identifying these fibroinflammatory circuits offers promising targets fo
This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors’ bone safety in this population.
The FDA has approved Roche’s obinutuzumab for active lupus nephritis in adults, offering a twice-yearly dosing regimen that achieved nearly 50% complete renal remission in trials, marking a significant advancement in lupus nephritis managem
A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicate
Achieving low lupus disease activity (LLDAS) at 12 months is an attainable target in lupus nephritis and independently predicts reduced relapse risk and preserved renal function, supporting its potential as a future treatment goal.
